Celanese claims that VitalDose excipients are based on EVA polymers and offer a wide degree of flexibility in the design of transdermal, subcutaneous implant and mucosal insert dosage forms.
Further, VitalDose offers customisable release properties and the potential for new delivery routes to be used in the development of pharmaceutical product line extensions and new concepts.
Celanese EVA Performance Polymers business general manager Mark Murray said that developing new routes of administration for existing products, or enhancing the bioavailability of newly developed yet poorly soluble drugs, is an important option that pharmaceutical companies consider as a strategy to maintain the success of their product franchises.
Celanese Office of Strategic Growth chief technology officer Jon Mortimer said that VitalDose offers a wide degree of flexibility in the design of controlled release dosage solutions.
Celanese produces specialty materials and chemical products for use in major industries and consumer applications.